DENVER–(BUSINESS WIRE)–HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce the launch of its highly anticipated CBD Gummy line.
Utilizing HempFusion’s proprietary broad-spectrum hemp extract, never an isolate, the Company’s new, great tasting gummies feature natural functional ingredients and premium flavors, two popular consumer driven trends. According to Brightfield Group, the CBD gummy market is set to achieve $500 million in sales in 2021, up 44% from 2020, and is expected to reach $1.8 billion in 2026.
“Now available from HempFusion.com, our gummy line is our newest revenue driver and is now shipping to major Food, Drug and Mass retail and convenience locations with further distribution planned across International Markets as well as ecommerce sites,” stated Jason Mitchell, N.D., Chief Executive Officer of HempFusion Wellness Inc. “We welcome consumers to learn more and try our delicious new Elderberry CBD Immune Support and Summer Cherry Gummies for themselves by visiting HempFusion.com. Use code ‘Gummyrush25’ to enjoy 25% off plus free shipping through September 4, 2021.”
“Our customers have demonstrated positive initial feedback to our Gummy products in the areas of taste, packaging, assortment and pricing,” added Jon Visser, Chief Revenue Officer at HempFusion Wellness Inc. “Our decision to manufacture these products into three different sizes gives us access into potentially multiple locations within a retailer to drive consumer trial and up-size conversion. Specifically, the single package appeals to retail channels such as Convenience, Frontend Checkstand, Airport and Hospitality that focus primarily on single-use products for purchase.”
HempFusion’s new Elderberry CBD Immune Support Gummies include 10 mg of broad spectrum CBD alongside 100 mg of elderberry extract, a functional ingredient scientifically studied to support the immune system. In a general population study of 5,000 consumers by Evergi, Brightfield Group’s wellness platform, “immune boosting” benefits were the second most popular health claim that consumers look for when purchasing food, beverage and supplement products.
In addition to elderberry, HempFusion’s new line includes Summer Cherry Gummies, a sweet and tart flavor experience delivering 10 mg of HempFusion’s best-in-class broad spectrum CBD in a delicious chew.
HempFusion’s premium CBD gummies available in 30 and six count packages for $29.99 and $9.99 respectively. Single count packages, priced at $3.49, will be available at convenience stores for consumers interested in sampling HempFusion gummies.
HempFusion gummies contain no THC (tested to be less than .01%), are vegan and free of gluten, gelatin, and artificial colors, flavors, and sweeteners.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the Company’s CBD gummy line as a revenue driver, shipment of the gummy line to major Food, Drug and Mass retail and convenience locations, planned distribution of the gummy line across International Markets and ecommerce sites, potential access to multiple locations within retailers through product sizing and the Company’s other plans, focus and objectives.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in the annual information form of the Company dated March 31, 2021 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.